Background: Trough (C0) monitoring is not optimal for therapeutic drug monitoring of
INTRODUCTION
The calcineurin inhibitor tacrolimus is widely used for immunosuppression after orthotopic liver transplantation (OLT). Tacrolimus has a small therapeutic window, underexposure can result in rejection whereas overexposure can lead to adverse effects, especially nephrotoxicity. Accurate monitoring of this drug is therefore mandatory to improve clinical outcome 1, 2 . For cyclosporine, another calcineurin inhibitor, different methods have been developed to estimate systemic exposure using the area under the concentration-time curve (AUC), which can result in better clinical outcome in terms of reduction of toxicity and improved renal function [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Monitoring tacrolimus (FK-506, Prograf Astellas Pharma, Stainer, UK) therapy is still based on trough concentration (C0) monitoring in most centers. However, recent data have shown that C0 does not accurately reflect systemic exposure over the first 12 hours after dosing 14 .
Patients with similar C0 tacrolimus concentrations can have very different AUCs. Other studies in liver and kidney transplantation have suggested different time points at which better predictions of systemic exposure of tacrolimus can be made than using trough concentrations [14] [15] [16] [17] .
When better prediction of total systemic exposure of tacrolimus in the first 12 hours after dosing is possible, we may see improved clinical outcome in terms of fewer rejection episodes and lowering of toxicity.
The aim of the present study was to examine which single time point or combination of time points best reflect systemic exposure of tacrolimus by calculating the area under the curve and then to develop and validate a new, flexible, and accurate limited sampling model, which is easy to apply in clinical practice as we have shown previously for cyclosporine 18, 19 . Assay (IMx; Abbott Diagnostics, Abbott Park, IL). To lower the influence of meals, the patients were instructed to take only a light breakfast-tea and a biscuit-on the morning the AUC was measured, and until the 2 hours sample (C2), no additional food or drinks were taken 21 .
PATIENTS AND METHODS
AUC 0-12h of all 23 curves were calculated with the trapezoidal rule using the software package MW\Pharm version 3.60 (Mediware, Groningen, The Netherlands) 22, 23 . The patients were assigned to a group on the basis of a climbing AUC/dose ratio in a 1:1 fashion. Starting with a low ratio, the first patient entered one group and the second patient entered the other group until all patients were divided among the two groups.
Therewith, two groups with a comparable clearance distribution were formed: group 1 (n = 11) and group 2 (n = 12). Data from group 1 were used to calculate limited sampling formulae (LSF) and for the development of a population pharmacokinetic (POP-PK) model. Data from group 2 were used to validate this POP-PK model.
The POP-PK model integrated all available information obtained from PK sampling and generated a population model. This model was used to obtain individualized pharmacokinetic parameters (individualized PK model based on Bayesian fitting) on the basis of new PK information (samples at single or multiple time points) from new patients, allowing individualized dose advice to be given. This Bayesian approach is a flexible alternative to methods using limited sampling formulae that have fixed sampling times 24 .
Several single blood sampling time points (C0, C1, C2, C3, C4, C6, and C8) and combinations of these samples were examined, 23 in total. We compared the performance of limited sampling models (LSM) with the more rigid limited sampling formulae. Finally, we performed a validation step and calculated a new target range as a basis for future implementation in clinical practice.
Limited Sampling Formulae
Using multiple regression analysis (SPSS software; SPSS Inc., Chicago, IL) for group 1, 
Limited Sampling Models
Using the "Kinpop module" of MW\Pharm, a population two-compartment model with first-order absorption pharmacokinetics and without a lag time was calculated from the tacrolimus dosing, body weight, and blood concentration values of group 1. This program uses an iterative two-stage Bayesian procedure and calculates means, medians, and standard deviations of the pharmacokinetic parameters 25 . During this procedure, pharmacokinetic parameters were set to be distributed log-normally, and bioavailability was fixed for tacrolimus at 0.23 as a result of the absence of intravenous data and on the basis of literature values 26 .
The calculated mean POP-PK parameters based on group 1 were individualized for the 12 patients of group 2 based on tacrolimus dosing and weight and one or a combination of measured blood concentration as mentioned for LSF.
AUCs (µg/L*h) for group 2 were calculated using the following formula: 
RESULTS
Using multiple regression analysis, LSFs were calculated from 11 curves (group 1)
based on one or a combination of measured blood concentrations. A few examples are shown in Table 1 . The results of the performance in estimating the gold standard AUC 0-12h (derived by the trapezoidal rule) of these LSFs are shown in the lower part of Table 2 .
The best single point markers for tacrolimus monitoring in terms of predicting systemic exposure (gold standard AUC 0-12h ) to tacrolimus using LSF were C4 The calculated mean POP-PK parameters based on group 1 are shown in Table 3 . The upper part of Table 2 shows the performance of the individualized POP-PK model (LSM) in estimating the gold standard AUC 0-12h , the MPE and MAPE for single-and multiplepoint sampling, validated on 12 patients (group 2).
The best single point samples in terms of estimating systemic tacrolimus exposure using LSM appeared to be C4 and C6, which show excellent performance with the gold standard AUC 0-12h (both r 2 = 0.97, P < 0.05) with excellent precision and bias (MPE/MAPE 0/7 and 1/5) (Figure 2 ).
Except for LSM 0 + 1 h, all examined multiple-point LSMs showed excellent performance in estimating the gold standard AUC 0-12h (Table 2; 
DISCUSSION
In this study, we demonstrated that C0 monitoring for tacrolimus after liver transplantation is not precise and does not accurately reflect systemic exposure. We developed and validated individualized POP-PK models based on C4 or C6, which appear to accurately reflect systemic exposure of tacrolimus with excellent precision and bias.
Recent studies on tacrolimus monitoring have suggested that trough concentrations, as currently used in most centers for therapeutic drug monitoring of tacrolimus, are not the best estimators of systemic exposure of this drug. These studies have involved different types of organ transplantation and vary in time after transplantation [28] [29] [30] . In our study, C0 monitoring did not have a good performance in estimating AUC 0-12h without using LSF and LSM (r 2 = 0.69), or with using LSF (r 2 = 0.68 [MPE/MAPE 5/17]).
Performance of C0 with AUC 0-12h using LSM seems to be acceptable (r 2 = 0.87), but concentrating on MPE and MAPE, we conclude that the prediction precision (MAPE) is not in an acceptable range of ± 10% (MAPE 14%). finding that sampling between 4 and 6 hours postdosing seems optimal is in line with two other studies that suggested C4 and C5 sampling, respectively 15, 16 . Our model has the advantage that it is very flexible. Others also found C0 insufficient in different patient populations 16, 17 . Likewise, in cyclosporine monitoring, C0 and even C2 monitoring did not appear to be optimal, and several methods for optimizing therapeutic drug monitoring were developed by our group and others 3, 6, 7, 13, 19 .
A limitation of our models and formulae is that these were developed and validated in two small independent groups of stable patients more than 6 months after liver transplantation. Given the considerable changes in tacrolimus kinetics shortly after transplantation, we cannot recommend using these models in less stable patients or There is no need to take the blood sample exactly on time as long as the dosing and blood sampling time are recorded. These factors, in combination with the adequate performance of the model in the outpatient setting, which is normally a source of variability, provides a tool for adequate monitoring of tacrolimus.
The calculated AUC target range based on C0 monitoring (90-195 h*µg/L) is rather wide, which also suggests that C0 monitoring is not the optimal way for therapeutic drug monitoring of tacrolimus. In kidney transplantation in our clinic, for stable patients, a target AUC of 125 h*µg/L is adhered to (range, 100-150 h*µg/L), corresponding to a trough concentration of 7.5 µg/L 17 .
Currently, in the field of OLT, a trend with regard to reduction in calcineurin inhibition is noticeable. In a review article from Staatz et al, lower targets are described for liver transplantation compared with kidney transplantation 31 . With respect to this trend, and after observing Figure 3 , we decided to adopt a new target, slightly lower than used for kidney transplantation, in the stable period more than 6 weeks posttransplantation 17 and also lower than the range corresponding with C0 = 5 to 10 µg/L, which we were using in our clinic. The new target is visualized in Figure 3 and the clinical consequences will be studied prospectively.
The current trend toward lower target ranges underlines the need for precise monitoring, because tacrolimus underexposure should be avoided with respect to the prevention of rejection episodes. High tacrolimus exposure should be avoided as well, especially in the stable phase post-OLT, with regard to clinical toxicity such as nephrotoxicity, which could have a clear negative impact on patient and graft survival 1,2 .
With more accurate prediction of systemic exposure of tacrolimus in the first 12 hours after dosing with the individualized LSMs C4 or C6, we have developed we expect improvement in clinical outcome such as decrease in rejection rate, less (nephro)toxicity, and fewer infections. We are planning further validation with a prospective, randomized, controlled trial comparing C0 and LSM 4 h (or 6 h) monitoring, which includes clinical outcome parameters such as renal function, blood pressure, rejection, and laboratory parameters.
